Global Aflibercept Biosimilars Market Insights, Forecast to 2034
Aflibercept is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It is an inhibitor of vascular endothelial growth factor (VEGF).
Global Aflibercept Biosimilars market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Aflibercept Biosimilars industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Aflibercept Biosimilars market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Aflibercept Biosimilars market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Bayer
Roche
Regeneron
Sanofi
Novartis
Sartorius
Amgen
Samsung Bioepis
Mylan
Formycon
Coherus BioSciences
Cadila Pharmaceuticals
Hetero
Biocon
Gene Techno Science
Qilu Pharmaceutical
Segment by Type
Intravitreal Injection
Intravenous Injection
Segment by Application
Wet Macular Degeneration
Metastatic Colorectal Cancer
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Aflibercept Biosimilars plant distribution, commercial date of Aflibercept Biosimilars, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Aflibercept Biosimilars introduction, etc. Aflibercept Biosimilars Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Aflibercept Biosimilars
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Table of Content
1 Study Coverage
1.1 Aflibercept Biosimilars Product Introduction
1.2 Market by Type
1.2.1 Global Aflibercept Biosimilars Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Intravitreal Injection
1.2.3 Intravenous Injection
1.3 Market by Application
1.3.1 Global Aflibercept Biosimilars Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Wet Macular Degeneration
1.3.3 Metastatic Colorectal Cancer
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Aflibercept Biosimilars Sales Estimates and Forecasts 2018-2029
2.2 Global Aflibercept Biosimilars Revenue by Region
2.2.1 Global Aflibercept Biosimilars Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Aflibercept Biosimilars Revenue by Region (2018-2024)
2.2.3 Global Aflibercept Biosimilars Revenue by Region (2024-2029)
2.2.4 Global Aflibercept Biosimilars Revenue Market Share by Region (2018-2029)
2.3 Global Aflibercept Biosimilars Sales Estimates and Forecasts 2018-2029
2.4 Global Aflibercept Biosimilars Sales by Region
2.4.1 Global Aflibercept Biosimilars Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Aflibercept Biosimilars Sales by Region (2018-2024)
2.4.3 Global Aflibercept Biosimilars Sales by Region (2024-2029)
2.4.4 Global Aflibercept Biosimilars Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Aflibercept Biosimilars Sales by Manufacturers
3.1.1 Global Aflibercept Biosimilars Sales by Manufacturers (2018-2024)
3.1.2 Global Aflibercept Biosimilars Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Aflibercept Biosimilars in 2022
3.2 Global Aflibercept Biosimilars Revenue by Manufacturers
3.2.1 Global Aflibercept Biosimilars Revenue by Manufacturers (2018-2024)
3.2.2 Global Aflibercept Biosimilars Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Aflibercept Biosimilars Revenue in 2022
3.3 Global Key Players of Aflibercept Biosimilars, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Aflibercept Biosimilars Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Aflibercept Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Aflibercept Biosimilars, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Aflibercept Biosimilars, Product Offered and Application
3.8 Global Key Manufacturers of Aflibercept Biosimilars, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Aflibercept Biosimilars Sales by Type
4.1.1 Global Aflibercept Biosimilars Historical Sales by Type (2018-2024)
4.1.2 Global Aflibercept Biosimilars Forecasted Sales by Type (2024-2029)
4.1.3 Global Aflibercept Biosimilars Sales Market Share by Type (2018-2029)
4.2 Global Aflibercept Biosimilars Revenue by Type
4.2.1 Global Aflibercept Biosimilars Historical Revenue by Type (2018-2024)
4.2.2 Global Aflibercept Biosimilars Forecasted Revenue by Type (2024-2029)
4.2.3 Global Aflibercept Biosimilars Revenue Market Share by Type (2018-2029)
4.3 Global Aflibercept Biosimilars Price by Type
4.3.1 Global Aflibercept Biosimilars Price by Type (2018-2024)
4.3.2 Global Aflibercept Biosimilars Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Aflibercept Biosimilars Sales by Application
5.1.1 Global Aflibercept Biosimilars Historical Sales by Application (2018-2024)
5.1.2 Global Aflibercept Biosimilars Forecasted Sales by Application (2024-2029)
5.1.3 Global Aflibercept Biosimilars Sales Market Share by Application (2018-2029)
5.2 Global Aflibercept Biosimilars Revenue by Application
5.2.1 Global Aflibercept Biosimilars Historical Revenue by Application (2018-2024)
5.2.2 Global Aflibercept Biosimilars Forecasted Revenue by Application (2024-2029)
5.2.3 Global Aflibercept Biosimilars Revenue Market Share by Application (2018-2029)
5.3 Global Aflibercept Biosimilars Price by Application
5.3.1 Global Aflibercept Biosimilars Price by Application (2018-2024)
5.3.2 Global Aflibercept Biosimilars Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Aflibercept Biosimilars Market Size by Type
6.1.1 US & Canada Aflibercept Biosimilars Sales by Type (2018-2029)
6.1.2 US & Canada Aflibercept Biosimilars Revenue by Type (2018-2029)
6.2 US & Canada Aflibercept Biosimilars Market Size by Application
6.2.1 US & Canada Aflibercept Biosimilars Sales by Application (2018-2029)
6.2.2 US & Canada Aflibercept Biosimilars Revenue by Application (2018-2029)
6.3 US & Canada Aflibercept Biosimilars Market Size by Country
6.3.1 US & Canada Aflibercept Biosimilars Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Aflibercept Biosimilars Sales by Country (2018-2029)
6.3.3 US & Canada Aflibercept Biosimilars Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Aflibercept Biosimilars Market Size by Type
7.1.1 Europe Aflibercept Biosimilars Sales by Type (2018-2029)
7.1.2 Europe Aflibercept Biosimilars Revenue by Type (2018-2029)
7.2 Europe Aflibercept Biosimilars Market Size by Application
7.2.1 Europe Aflibercept Biosimilars Sales by Application (2018-2029)
7.2.2 Europe Aflibercept Biosimilars Revenue by Application (2018-2029)
7.3 Europe Aflibercept Biosimilars Market Size by Country
7.3.1 Europe Aflibercept Biosimilars Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Aflibercept Biosimilars Sales by Country (2018-2029)
7.3.3 Europe Aflibercept Biosimilars Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Aflibercept Biosimilars Market Size
8.1.1 China Aflibercept Biosimilars Sales (2018-2029)
8.1.2 China Aflibercept Biosimilars Revenue (2018-2029)
8.2 China Aflibercept Biosimilars Market Size by Application
8.2.1 China Aflibercept Biosimilars Sales by Application (2018-2029)
8.2.2 China Aflibercept Biosimilars Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Aflibercept Biosimilars Market Size by Type
9.1.1 Asia Aflibercept Biosimilars Sales by Type (2018-2029)
9.1.2 Asia Aflibercept Biosimilars Revenue by Type (2018-2029)
9.2 Asia Aflibercept Biosimilars Market Size by Application
9.2.1 Asia Aflibercept Biosimilars Sales by Application (2018-2029)
9.2.2 Asia Aflibercept Biosimilars Revenue by Application (2018-2029)
9.3 Asia Aflibercept Biosimilars Sales by Region
9.3.1 Asia Aflibercept Biosimilars Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Aflibercept Biosimilars Revenue by Region (2018-2029)
9.3.3 Asia Aflibercept Biosimilars Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Aflibercept Biosimilars Market Size by Type
10.1.1 Middle East, Africa and Latin America Aflibercept Biosimilars Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Aflibercept Biosimilars Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Aflibercept Biosimilars Market Size by Application
10.2.1 Middle East, Africa and Latin America Aflibercept Biosimilars Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Aflibercept Biosimilars Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Aflibercept Biosimilars Sales by Country
10.3.1 Middle East, Africa and Latin America Aflibercept Biosimilars Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Aflibercept Biosimilars Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Aflibercept Biosimilars Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Bayer
11.1.1 Bayer Company Information
11.1.2 Bayer Overview
11.1.3 Bayer Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Bayer Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bayer Recent Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche Overview
11.2.3 Roche Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Roche Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Roche Recent Developments
11.3 Regeneron
11.3.1 Regeneron Company Information
11.3.2 Regeneron Overview
11.3.3 Regeneron Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Regeneron Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Regeneron Recent Developments
11.4 Sanofi
11.4.1 Sanofi Company Information
11.4.2 Sanofi Overview
11.4.3 Sanofi Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Sanofi Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Sanofi Recent Developments
11.5 Novartis
11.5.1 Novartis Company Information
11.5.2 Novartis Overview
11.5.3 Novartis Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Novartis Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Novartis Recent Developments
11.6 Sartorius
11.6.1 Sartorius Company Information
11.6.2 Sartorius Overview
11.6.3 Sartorius Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Sartorius Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Sartorius Recent Developments
11.7 Amgen
11.7.1 Amgen Company Information
11.7.2 Amgen Overview
11.7.3 Amgen Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Amgen Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Amgen Recent Developments
11.8 Samsung Bioepis
11.8.1 Samsung Bioepis Company Information
11.8.2 Samsung Bioepis Overview
11.8.3 Samsung Bioepis Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Samsung Bioepis Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Samsung Bioepis Recent Developments
11.9 Mylan
11.9.1 Mylan Company Information
11.9.2 Mylan Overview
11.9.3 Mylan Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Mylan Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Mylan Recent Developments
11.10 Formycon
11.10.1 Formycon Company Information
11.10.2 Formycon Overview
11.10.3 Formycon Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Formycon Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Formycon Recent Developments
11.11 Coherus BioSciences
11.11.1 Coherus BioSciences Company Information
11.11.2 Coherus BioSciences Overview
11.11.3 Coherus BioSciences Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 Coherus BioSciences Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Coherus BioSciences Recent Developments
11.12 Cadila Pharmaceuticals
11.12.1 Cadila Pharmaceuticals Company Information
11.12.2 Cadila Pharmaceuticals Overview
11.12.3 Cadila Pharmaceuticals Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 Cadila Pharmaceuticals Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Cadila Pharmaceuticals Recent Developments
11.13 Hetero
11.13.1 Hetero Company Information
11.13.2 Hetero Overview
11.13.3 Hetero Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.13.4 Hetero Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Hetero Recent Developments
11.14 Biocon
11.14.1 Biocon Company Information
11.14.2 Biocon Overview
11.14.3 Biocon Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.14.4 Biocon Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Biocon Recent Developments
11.15 Gene Techno Science
11.15.1 Gene Techno Science Company Information
11.15.2 Gene Techno Science Overview
11.15.3 Gene Techno Science Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.15.4 Gene Techno Science Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Gene Techno Science Recent Developments
11.16 Qilu Pharmaceutical
11.16.1 Qilu Pharmaceutical Company Information
11.16.2 Qilu Pharmaceutical Overview
11.16.3 Qilu Pharmaceutical Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.16.4 Qilu Pharmaceutical Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Qilu Pharmaceutical Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Aflibercept Biosimilars Industry Chain Analysis
12.2 Aflibercept Biosimilars Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Aflibercept Biosimilars Production Mode & Process
12.4 Aflibercept Biosimilars Sales and Marketing
12.4.1 Aflibercept Biosimilars Sales Channels
12.4.2 Aflibercept Biosimilars Distributors
12.5 Aflibercept Biosimilars Customers
13 Market Dynamics
13.1 Aflibercept Biosimilars Industry Trends
13.2 Aflibercept Biosimilars Market Drivers
13.3 Aflibercept Biosimilars Market Challenges
13.4 Aflibercept Biosimilars Market Restraints
14 Key Findings in The Global Aflibercept Biosimilars Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Figure
List of Tables
Table 1. Global Aflibercept Biosimilars Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Intravitreal Injection
Table 3. Major Manufacturers of Intravenous Injection
Table 4. Global Aflibercept Biosimilars Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global Aflibercept Biosimilars Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Aflibercept Biosimilars Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Aflibercept Biosimilars Revenue by Region (2024-2029) & (US$ Million)
Table 8. Global Aflibercept Biosimilars Revenue Market Share by Region (2018-2024)
Table 9. Global Aflibercept Biosimilars Revenue Market Share by Region (2024-2029)
Table 10. Global Aflibercept Biosimilars Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global Aflibercept Biosimilars Sales by Region (2018-2024) & (K Units)
Table 12. Global Aflibercept Biosimilars Sales by Region (2024-2029) & (K Units)
Table 13. Global Aflibercept Biosimilars Sales Market Share by Region (2018-2024)
Table 14. Global Aflibercept Biosimilars Sales Market Share by Region (2024-2029)
Table 15. Global Aflibercept Biosimilars Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global Aflibercept Biosimilars Sales Share by Manufacturers (2018-2024)
Table 17. Global Aflibercept Biosimilars Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Aflibercept Biosimilars Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of Aflibercept Biosimilars, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. Aflibercept Biosimilars Price by Manufacturers 2018-2024 (USD/Unit)
Table 21. Global Aflibercept Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Aflibercept Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Aflibercept Biosimilars as of 2022)
Table 23. Global Key Manufacturers of Aflibercept Biosimilars, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Aflibercept Biosimilars, Product Offered and Application
Table 25. Global Key Manufacturers of Aflibercept Biosimilars, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Aflibercept Biosimilars Sales by Type (2018-2024) & (K Units)
Table 28. Global Aflibercept Biosimilars Sales by Type (2024-2029) & (K Units)
Table 29. Global Aflibercept Biosimilars Sales Share by Type (2018-2024)
Table 30. Global Aflibercept Biosimilars Sales Share by Type (2024-2029)
Table 31. Global Aflibercept Biosimilars Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Aflibercept Biosimilars Revenue by Type (2024-2029) & (US$ Million)
Table 33. Global Aflibercept Biosimilars Revenue Share by Type (2018-2024)
Table 34. Global Aflibercept Biosimilars Revenue Share by Type (2024-2029)
Table 35. Aflibercept Biosimilars Price by Type (2018-2024) & (USD/Unit)
Table 36. Global Aflibercept Biosimilars Price Forecast by Type (2024-2029) & (USD/Unit)
Table 37. Global Aflibercept Biosimilars Sales by Application (2018-2024) & (K Units)
Table 38. Global Aflibercept Biosimilars Sales by Application (2024-2029) & (K Units)
Table 39. Global Aflibercept Biosimilars Sales Share by Application (2018-2024)
Table 40. Global Aflibercept Biosimilars Sales Share by Application (2024-2029)
Table 41. Global Aflibercept Biosimilars Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Aflibercept Biosimilars Revenue by Application (2024-2029) & (US$ Million)
Table 43. Global Aflibercept Biosimilars Revenue Share by Application (2018-2024)
Table 44. Global Aflibercept Biosimilars Revenue Share by Application (2024-2029)
Table 45. Aflibercept Biosimilars Price by Application (2018-2024) & (USD/Unit)
Table 46. Global Aflibercept Biosimilars Price Forecast by Application (2024-2029) & (USD/Unit)
Table 47. US & Canada Aflibercept Biosimilars Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada Aflibercept Biosimilars Sales by Type (2024-2029) & (K Units)
Table 49. US & Canada Aflibercept Biosimilars Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada Aflibercept Biosimilars Revenue by Type (2024-2029) & (US$ Million)
Table 51. US & Canada Aflibercept Biosimilars Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada Aflibercept Biosimilars Sales by Application (2024-2029) & (K Units)
Table 53. US & Canada Aflibercept Biosimilars Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada Aflibercept Biosimilars Revenue by Application (2024-2029) & (US$ Million)
Table 55. US & Canada Aflibercept Biosimilars Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. US & Canada Aflibercept Biosimilars Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada Aflibercept Biosimilars Revenue by Country (2024-2029) & (US$ Million)
Table 58. US & Canada Aflibercept Biosimilars Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada Aflibercept Biosimilars Sales by Country (2024-2029) & (K Units)
Table 60. Europe Aflibercept Biosimilars Sales by Type (2018-2024) & (K Units)
Table 61. Europe Aflibercept Biosimilars Sales by Type (2024-2029) & (K Units)
Table 62. Europe Aflibercept Biosimilars Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe Aflibercept Biosimilars Revenue by Type (2024-2029) & (US$ Million)
Table 64. Europe Aflibercept Biosimilars Sales by Application (2018-2024) & (K Units)
Table 65. Europe Aflibercept Biosimilars Sales by Application (2024-2029) & (K Units)
Table 66. Europe Aflibercept Biosimilars Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe Aflibercept Biosimilars Revenue by Application (2024-2029) & (US$ Million)
Table 68. Europe Aflibercept Biosimilars Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 69. Europe Aflibercept Biosimilars Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe Aflibercept Biosimilars Revenue by Country (2024-2029) & (US$ Million)
Table 71. Europe Aflibercept Biosimilars Sales by Country (2018-2024) & (K Units)
Table 72. Europe Aflibercept Biosimilars Sales by Country (2024-2029) & (K Units)
Table 73. China Aflibercept Biosimilars Sales by Type (2018-2024) & (K Units)
Table 74. China Aflibercept Biosimilars Sales by Type (2024-2029) & (K Units)
Table 75. China Aflibercept Biosimilars Revenue by Type (2018-2024) & (US$ Million)
Table 76. China Aflibercept Biosimilars Revenue by Type (2024-2029) & (US$ Million)
Table 77. China Aflibercept Biosimilars Sales by Application (2018-2024) & (K Units)
Table 78. China Aflibercept Biosimilars Sales by Application (2024-2029) & (K Units)
Table 79. China Aflibercept Biosimilars Revenue by Application (2018-2024) & (US$ Million)
Table 80. China Aflibercept Biosimilars Revenue by Application (2024-2029) & (US$ Million)
Table 81. Asia Aflibercept Biosimilars Sales by Type (2018-2024) & (K Units)
Table 82. Asia Aflibercept Biosimilars Sales by Type (2024-2029) & (K Units)
Table 83. Asia Aflibercept Biosimilars Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia Aflibercept Biosimilars Revenue by Type (2024-2029) & (US$ Million)
Table 85. Asia Aflibercept Biosimilars Sales by Application (2018-2024) & (K Units)
Table 86. Asia Aflibercept Biosimilars Sales by Application (2024-2029) & (K Units)
Table 87. Asia Aflibercept Biosimilars Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia Aflibercept Biosimilars Revenue by Application (2024-2029) & (US$ Million)
Table 89. Asia Aflibercept Biosimilars Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 90. Asia Aflibercept Biosimilars Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia Aflibercept Biosimilars Revenue by Region (2024-2029) & (US$ Million)
Table 92. Asia Aflibercept Biosimilars Sales by Region (2018-2024) & (K Units)
Table 93. Asia Aflibercept Biosimilars Sales by Region (2024-2029) & (K Units)
Table 94. Middle East, Africa and Latin America Aflibercept Biosimilars Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America Aflibercept Biosimilars Sales by Type (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Aflibercept Biosimilars Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America Aflibercept Biosimilars Revenue by Type (2024-2029) & (US$ Million)
Table 98. Middle East, Africa and Latin America Aflibercept Biosimilars Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America Aflibercept Biosimilars Sales by Application (2024-2029) & (K Units)
Table 100. Middle East, Africa and Latin America Aflibercept Biosimilars Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Aflibercept Biosimilars Revenue by Application (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America Aflibercept Biosimilars Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 103. Middle East, Africa and Latin America Aflibercept Biosimilars Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Aflibercept Biosimilars Revenue by Country (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America Aflibercept Biosimilars Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Aflibercept Biosimilars Sales by Country (2024-2029) & (K Units)
Table 107. Bayer Company Information
Table 108. Bayer Description and Major Businesses
Table 109. Bayer Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 110. Bayer Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Bayer Recent Developments
Table 112. Roche Company Information
Table 113. Roche Description and Major Businesses
Table 114. Roche Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 115. Roche Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Roche Recent Developments
Table 117. Regeneron Company Information
Table 118. Regeneron Description and Major Businesses
Table 119. Regeneron Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 120. Regeneron Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Regeneron Recent Developments
Table 122. Sanofi Company Information
Table 123. Sanofi Description and Major Businesses
Table 124. Sanofi Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 125. Sanofi Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Sanofi Recent Developments
Table 127. Novartis Company Information
Table 128. Novartis Description and Major Businesses
Table 129. Novartis Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 130. Novartis Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Novartis Recent Developments
Table 132. Sartorius Company Information
Table 133. Sartorius Description and Major Businesses
Table 134. Sartorius Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 135. Sartorius Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Sartorius Recent Developments
Table 137. Amgen Company Information
Table 138. Amgen Description and Major Businesses
Table 139. Amgen Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 140. Amgen Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Amgen Recent Developments
Table 142. Samsung Bioepis Company Information
Table 143. Samsung Bioepis Description and Major Businesses
Table 144. Samsung Bioepis Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 145. Samsung Bioepis Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Samsung Bioepis Recent Developments
Table 147. Mylan Company Information
Table 148. Mylan Description and Major Businesses
Table 149. Mylan Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 150. Mylan Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Mylan Recent Developments
Table 152. Formycon Company Information
Table 153. Formycon Description and Major Businesses
Table 154. Formycon Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 155. Formycon Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Formycon Recent Developments
Table 157. Coherus BioSciences Company Information
Table 158. Coherus BioSciences Description and Major Businesses
Table 159. Coherus BioSciences Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 160. Coherus BioSciences Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Coherus BioSciences Recent Developments
Table 162. Cadila Pharmaceuticals Company Information
Table 163. Cadila Pharmaceuticals Description and Major Businesses
Table 164. Cadila Pharmaceuticals Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 165. Cadila Pharmaceuticals Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. Cadila Pharmaceuticals Recent Developments
Table 167. Hetero Company Information
Table 168. Hetero Description and Major Businesses
Table 169. Hetero Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 170. Hetero Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. Hetero Recent Developments
Table 172. Biocon Company Information
Table 173. Biocon Description and Major Businesses
Table 174. Biocon Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 175. Biocon Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 176. Biocon Recent Developments
Table 177. Gene Techno Science Company Information
Table 178. Gene Techno Science Description and Major Businesses
Table 179. Gene Techno Science Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 180. Gene Techno Science Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 181. Gene Techno Science Recent Developments
Table 182. Qilu Pharmaceutical Company Information
Table 183. Qilu Pharmaceutical Description and Major Businesses
Table 184. Qilu Pharmaceutical Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 185. Qilu Pharmaceutical Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 186. Qilu Pharmaceutical Recent Developments
Table 187. Key Raw Materials Lists
Table 188. Raw Materials Key Suppliers Lists
Table 189. Aflibercept Biosimilars Distributors List
Table 190. Aflibercept Biosimilars Customers List
Table 191. Aflibercept Biosimilars Market Trends
Table 192. Aflibercept Biosimilars Market Drivers
Table 193. Aflibercept Biosimilars Market Challenges
Table 194. Aflibercept Biosimilars Market Restraints
Table 195. Research Programs/Design for This Report
Table 196. Key Data Information from Secondary Sources
Table 197. Key Data Information from Primary Sources
List of Figures
Figure 1. Aflibercept Biosimilars Product Picture
Figure 2. Global Aflibercept Biosimilars Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Aflibercept Biosimilars Market Share by Type in 2022 & 2029
Figure 4. Intravitreal Injection Product Picture
Figure 5. Intravenous Injection Product Picture
Figure 6. Global Aflibercept Biosimilars Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global Aflibercept Biosimilars Market Share by Application in 2022 & 2029
Figure 8. Wet Macular Degeneration
Figure 9. Metastatic Colorectal Cancer
Figure 10. Aflibercept Biosimilars Report Years Considered
Figure 11. Global Aflibercept Biosimilars Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global Aflibercept Biosimilars Revenue 2018-2029 (US$ Million)
Figure 13. Global Aflibercept Biosimilars Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 14. Global Aflibercept Biosimilars Revenue Market Share by Region (2018-2029)
Figure 15. Global Aflibercept Biosimilars Sales 2018-2029 ((K Units)
Figure 16. Global Aflibercept Biosimilars Sales Market Share by Region (2018-2029)
Figure 17. US & Canada Aflibercept Biosimilars Sales YoY (2018-2029) & (K Units)
Figure 18. US & Canada Aflibercept Biosimilars Revenue YoY (2018-2029) & (US$ Million)
Figure 19. Europe Aflibercept Biosimilars Sales YoY (2018-2029) & (K Units)
Figure 20. Europe Aflibercept Biosimilars Revenue YoY (2018-2029) & (US$ Million)
Figure 21. China Aflibercept Biosimilars Sales YoY (2018-2029) & (K Units)
Figure 22. China Aflibercept Biosimilars Revenue YoY (2018-2029) & (US$ Million)
Figure 23. Asia (excluding China) Aflibercept Biosimilars Sales YoY (2018-2029) & (K Units)
Figure 24. Asia (excluding China) Aflibercept Biosimilars Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Middle East, Africa and Latin America Aflibercept Biosimilars Sales YoY (2018-2029) & (K Units)
Figure 26. Middle East, Africa and Latin America Aflibercept Biosimilars Revenue YoY (2018-2029) & (US$ Million)
Figure 27. The Aflibercept Biosimilars Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 28. The Top 5 and 10 Largest Manufacturers of Aflibercept Biosimilars in the World: Market Share by Aflibercept Biosimilars Revenue in 2022
Figure 29. Global Aflibercept Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 30. Global Aflibercept Biosimilars Sales Market Share by Type (2018-2029)
Figure 31. Global Aflibercept Biosimilars Revenue Market Share by Type (2018-2029)
Figure 32. Global Aflibercept Biosimilars Sales Market Share by Application (2018-2029)
Figure 33. Global Aflibercept Biosimilars Revenue Market Share by Application (2018-2029)
Figure 34. US & Canada Aflibercept Biosimilars Sales Market Share by Type (2018-2029)
Figure 35. US & Canada Aflibercept Biosimilars Revenue Market Share by Type (2018-2029)
Figure 36. US & Canada Aflibercept Biosimilars Sales Market Share by Application (2018-2029)
Figure 37. US & Canada Aflibercept Biosimilars Revenue Market Share by Application (2018-2029)
Figure 38. US & Canada Aflibercept Biosimilars Revenue Share by Country (2018-2029)
Figure 39. US & Canada Aflibercept Biosimilars Sales Share by Country (2018-2029)
Figure 40. U.S. Aflibercept Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 41. Canada Aflibercept Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 42. Europe Aflibercept Biosimilars Sales Market Share by Type (2018-2029)
Figure 43. Europe Aflibercept Biosimilars Revenue Market Share by Type (2018-2029)
Figure 44. Europe Aflibercept Biosimilars Sales Market Share by Application (2018-2029)
Figure 45. Europe Aflibercept Biosimilars Revenue Market Share by Application (2018-2029)
Figure 46. Europe Aflibercept Biosimilars Revenue Share by Country (2018-2029)
Figure 47. Europe Aflibercept Biosimilars Sales Share by Country (2018-2029)
Figure 48. Germany Aflibercept Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 49. France Aflibercept Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 50. U.K. Aflibercept Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 51. Italy Aflibercept Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 52. Russia Aflibercept Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 53. China Aflibercept Biosimilars Sales Market Share by Type (2018-2029)
Figure 54. China Aflibercept Biosimilars Revenue Market Share by Type (2018-2029)
Figure 55. China Aflibercept Biosimilars Sales Market Share by Application (2018-2029)
Figure 56. China Aflibercept Biosimilars Revenue Market Share by Application (2018-2029)
Figure 57. Asia Aflibercept Biosimilars Sales Market Share by Type (2018-2029)
Figure 58. Asia Aflibercept Biosimilars Revenue Market Share by Type (2018-2029)
Figure 59. Asia Aflibercept Biosimilars Sales Market Share by Application (2018-2029)
Figure 60. Asia Aflibercept Biosimilars Revenue Market Share by Application (2018-2029)
Figure 61. Asia Aflibercept Biosimilars Revenue Share by Region (2018-2029)
Figure 62. Asia Aflibercept Biosimilars Sales Share by Region (2018-2029)
Figure 63. Japan Aflibercept Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 64. South Korea Aflibercept Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 65. China Taiwan Aflibercept Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 66. Southeast Asia Aflibercept Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 67. India Aflibercept Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 68. Middle East, Africa and Latin America Aflibercept Biosimilars Sales Market Share by Type (2018-2029)
Figure 69. Middle East, Africa and Latin America Aflibercept Biosimilars Revenue Market Share by Type (2018-2029)
Figure 70. Middle East, Africa and Latin America Aflibercept Biosimilars Sales Market Share by Application (2018-2029)
Figure 71. Middle East, Africa and Latin America Aflibercept Biosimilars Revenue Market Share by Application (2018-2029)
Figure 72. Middle East, Africa and Latin America Aflibercept Biosimilars Revenue Share by Country (2018-2029)
Figure 73. Middle East, Africa and Latin America Aflibercept Biosimilars Sales Share by Country (2018-2029)
Figure 74. Brazil Aflibercept Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 75. Mexico Aflibercept Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 76. Turkey Aflibercept Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 77. Israel Aflibercept Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 78. GCC Countries Aflibercept Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 79. Aflibercept Biosimilars Value Chain
Figure 80. Aflibercept Biosimilars Production Process
Figure 81. Channels of Distribution
Figure 82. Distributors Profiles
Figure 83. Bottom-up and Top-down Approaches for This Report
Figure 84. Data Triangulation
Figure 85. Key Executives Interviewed
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices